Summary of NACI statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age

Download in PDF format
(498 KB, 6 pages)

Organization: Public Health Agency of Canada
Cat.: HP5-139/2-2022E-PDF
ISBN: 978-0-660-44455-0
Pub.: 220313
Published: 2022-07-14

Publication date: July 14, 2022

On this page

Overview

  • For children 6 months to 5 years of age, NACI recommends that:
    1. A primary series of two doses of Moderna Spikevax (25 mcg) COVID-19 vaccine may be offered to children 6 months to 5 years of age who do not have contraindications to the vaccine, with a dosing interval of at least 8 weeks between the first and second dose. (Discretionary NACI recommendation)
    2. A primary series of three doses of Moderna Spikevax (25 mcg) COVID-19 vaccine may be offered to children 6 months to 5 years of age who are moderately to severely immunocompromised, with an interval of 4 to 8 weeks between each dose. (Discretionary NACI recommendation)
    3. At this time, Moderna Spikevax (25 mcg) COVID-19 vaccine should not routinely be given concurrently (i.e., same day) with other vaccines. (Strong NACI recommendation)
      • As this is a newly authorized COVID-19 vaccine in this age group, NACI recommends that Moderna Spikevax (25 mcg) COVID-19 vaccine should be given 14 days before or after a different vaccine. This will help to determine if a potential side effect is due to Moderna Spikevax (25 mcg) COVID-19 vaccine or a different vaccine. A shorter interval between the administration of Moderna Spikevax (25 mcg) vaccine and a different vaccine may be warranted in some circumstances at the discretion of a health care provider.

For the full statement, including supporting evidence and rationale, please see NACI Statement: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age.

For more information on NACI's recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

What you need to know

For the full statement, including supporting evidence and rationale, please see NACI Statement: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age.

For more information on NACI's recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

Quotes

"NACI is further expanding COVID-19 vaccine recommendations to include children six months to 5 years of age. While most children in this age group have relatively mild disease, some do experience severe illness, especially those with underlying medical conditions. NACI has carefully reviewed the available evidence, and recommends that vaccine may be offered to these young children using a similar approach as older age groups in terms of interval between doses, or interval between infection and doses. We expect that these recommendations will come as a relief to many parents who have been waiting for these vaccines to become available to protect their youngest children."

- Dr. Shelley Deeks, NACI Chair

"I welcome this advice from NACI on the use of the Moderna Spikevax COVID-19 vaccine for children aged 6 months to 5 years. Most children who are infected with the SARS-CoV-2 virus that causes COVID-19 have mild or no symptoms of the illness. However, some children experience severe COVID-19 disease and require hospitalization. Children who get COVID-19 can also develop a rare but serious condition called multisystem inflammatory syndrome in children (MIS-C) and while evidence in this age group is limited, may be at risk of post-COVID-19 condition (also known as long COVID). The availability of the Moderna Spikevax COVID-19 vaccine for children aged 6 months to 5 years provides families with a vaccine option to help protect their young children from COVID-19. It is very important that all children and their caregivers are supported during the decision-making process and that their decisions related to COVID-19 vaccination are respected. Health Canada, the Public Health Agency of Canada and the National Advisory Committee on Immunization will closely monitor the domestic and international rollout of the vaccine in young children."

- Dr. Theresa Tam, Chief Public Health Officer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: